other material
confidence high
sentiment positive
materiality 0.70
Arcus ARC-7 Phase 2 data: domvanalimab arms reduce PFS risk 28-33% in NSCLC
Arcus Biosciences, Inc.
- Doublet (domvanalimab+zimberelimab) showed 33% PFS risk reduction (HR 0.67) vs zimberelimab monotherapy in PD-L1≥50% NSCLC.
- Median PFS: 5.4 mo (Z), 9.3 mo (DZ), 9.9 mo (EDZ); 12-month PFS rates 25%, 41%, 44%.
- ORR: Z 30%, DZ 40%, EDZ 44%; median DoR not reached for DZ, 23.7 mo for EDZ.
- No unexpected safety signals; infusion-related reactions low (4-12%) across arms.
- Data from 150-patient randomized Phase 2 at ~18-month median follow-up.